A Retrospective Case Series Of High-Intensity Focused Ultrasound (HIFU) In Combination With Gemcitabine And Oxaliplatin (Gemox) On Treating Elderly Middle And Advanced Pancreatic Cancer
Authors:
Open Access
- 1 November 2019
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 9735-9745
Abstract
Purpose: This retrospective study was conducted to evaluate the safety and efficacy of high-intensity focused ultrasound (HIFU) ablation combined with Gemcitabine and Oxaliplatin (Gemox) for the treatment of middle and advanced pancreatic cancer in elderly patients. Methods: Forty-seven patients with pancreatic cancer treated with HIFU and Gemox were evaluated for inclusion, and 38 cases were finally included. The primary endpoint was safety. Secondary endpoints included the response rate, the clinical benefit response (CBR), overall survival (OS), progression-free survival (PFS). Results: After combination therapy of HIFU and Gemox, severe complications were rarely reported, and no treatment-related death occurred. The rate of three or four-degree myelosuppression was low, and no obvious impairment of hepatorenal function was observed. Pancreatitis and gastrointestinal injury did not occurred. The disease control rate (DCR) was estimated to be 76.3%, including complete remission (CR), partial remission (PR), stable disease (SD) in 1, 6, 22 cases, respectively. And the objective response rate (ORR) was 18.4%. The clinical benefit rate (CBR) was 68.4%, with the pain significantly relieved (PConclusion: Elderly patients (≥ 60 years old) with pancreatic cancer would experience tolerable toxicity and obtain good clinical benefits from the combination therapy of HIFU ablation and Gemox.Keywords
This publication has 47 references indexed in Scilit:
- Recent progress in pancreatic cancerCA: A Cancer Journal for Clinicians, 2013
- Safety Evaluation of High-Intensity Focused Ultrasound in Patients with Pancreatic CancerOncology Research and Treatment, 2013
- Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancerInternational Journal of Hyperthermia, 2011
- High-Intensity Focused Ultrasound Ablation: Effective and Safe Therapy for Solid Tumors in Difficult LocationsAmerican Journal of Roentgenology, 2010
- High intensity focused ultrasound ablation: A new therapeutic option for solid tumorsJournal of Cancer Research and Therapeutics, 2010
- Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experienceExpert Opinion on Drug Safety, 2009
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2009
- Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial—SAKK 44/00–CECOG/PAN.1.3.001Journal of Clinical Oncology, 2008
- Staging of Hepatocellular CarcinomaAnnals of Surgery, 2007
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000